Beat the analysts numbers by a significant margin. Analyst had RGDX doing only 5.4m in revs, they did $6.7m, so beat by 1.3m or 24% higher than his number. Beat by .04c on eps. Company is positioned to turn profitable this yr. Overall, I think these are good solid numbers. Once they add more sales reps and get some more pharma wins / contracts, we will see some great profitability for sure.
CG it is as u know the fact that RGDX has two streams of business one commercial like the GSK business and the other retail where reps sell the cancer dx kits to oncologists who in turn test their patients for type of cancer and mutation and protein markers that enables RGDX going forward to BEAT out their competition!
look at the sales revs this time...first time that retail is qoq a bit light but commercial is qoq stronger and both together gave a beat the street performance!
that is NOT to say that both could not together either shine or dissapoint, but to show that two income streams are better/safer than one any day and in this case in this quarterly, made for an overall good report!
for that Im happy and remain LONG 24,337shs net .856